```
                E KW-6002/CN

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
RN   155270-99-8  REGISTRY
ED   Entered STN:  24 May 1994
CN   1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-
diethyl-
     3,7-dihydro-7-methyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-
     dihydro-7-methyl-, (E)-
OTHER NAMES:
CN   Istradefylline
CN   KW 6002
FS   STEREOSEARCH
MF   C20 H24 N4 O4
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA,
       CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE,
IMSPATENTS,
       IMSRESEARCH, IPA, MEDLINE, MRCK*, RTECS*, TOXCENTER, USAN, USPAT2,
       USPATFULL
         (*File contains numerically searchable property data)

Double bond geometry as shown.
```




```
                SET EXPAND CONTINUOUS
                E KW 6002/CN
L1              1 S E15
                E PAROXETINE/CN

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
RN   61869-08-7  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,
     (3S,4R)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,
     (3S-trans)-
OTHER NAMES:
CN   (-)-Paroxetine
CN   (-)-trans-4-(4-Fluorophenyl)-3-(3,4-
methylenedioxyphenoxymethyl)piperidine
```

CN Aropax
CN Besitram
CN BRL 29060
CN Casbol
CN FG 7051
CN Frosinor
CN Motivan
CN Paroxetine
CN Paxetil
CN Paxil
CN PaxPar
FS STEREOSEARCH
DR 63952-24-9
MF C19 H20 F N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PS, REAXYSFILE*, RTECS*, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry. Rotation (-).



L2 1 S E27

FILE 'CAPLUS' ENTERED AT 11:22:08 ON 07 JUL 2011
L3 5 S L1 AND L2
L4 1 S US 20060241102/PN
E 5-HT ANTAGONISTS/IT
L5 3811 S 5-HT ANTAGONISTS/IT
E 5-HT REUPTAKE INHIBITORS/IT
L6 4404 S 5-HT REUPTAKE INHIBITORS/IT
L7 7867 S L5 OR L6
L8 6 S L1 AND L7
L9 3 S L8 NOT L3
L10 1 S L9 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN
AB It is intended to provide medicinal compns. and the like useful in treating depression which contain a compound having an antagonism to adenosine A2A receptor (for example, (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purin-2,6- dione) (I) or a pharmacol. acceptable salt thereof together with an antidepressant (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective

serotonin reuptake inhibitor, a selective noradrenaline reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin/noradrenaline reuptake inhibitor, a monoamine oxidase inhibitor or a serotonin 2 antagonist). The effect of combination of I 0.08 and venlafaxine hydrochloride 5 mg/kg on depression in mice in forced swim test was examined

ACCESSION NUMBER: 2005:99358 CAPLUS Full-text
DOCUMENT NUMBER: 142:162694
TITLE: Medicinal compositions containing adenosine A2A receptor antagonists and other antidepressants
INVENTOR(S): Kase, Hiroshi; Kobayashi, Minoru; Shiozaki, Shizuo; Mori, Akihisa; Seno, Naoki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009444	A1	20050203	WO 2004-JP10758	20040722
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2533117	A1	20050203	CA 2004-2533117	20040722
<--				
EP 1655029	A1	20060510	EP 2004-748023	20040722
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 4648193	B2	20110309	JP 2005-512077	20040722
<--				
US 20060241102	A1	20061026	US 2006-565239	20060119
<--				
NO 2006000958	A	20060425	NO 2006-958	20060227
<--				
PRIORITY APPLN. INFO.:			JP 2003-201549	A 20030725
<--				
			WO 2004-JP10758	W 20040722
<--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IPCI A61K0031-52 [ICM,7]; A61K0031-137 [ICS,7]; A61K0031-335 [ICS,7]; A61K0031-343 [ICS,7]; A61K0031-36 [ICS,7]; A61K0031-38 [ICS,7]; A61K0031-381 [ICS,7]; A61K0031-435 [ICS,7]; A61K0031-496 [ICS,7]; A61K0031-5375 [ICS,7]; A61K0031-55 [ICS,7]; A61K0031-553 [ICS,7]; A61P0025-24 [ICS,7]

```
IPCR A61K0031-137 [I,A]; A61K0031-335 [I,A]; A61K0031-343 [I,A]; A61K0031-36
     [I,A]; A61K0031-38 [I,A]; A61K0031-381 [I,A]; A61K0031-435 [I,A];
     A61K0031-496 [I,A]; A61K0031-52 [I,A]; A61K0031-5375 [I,A]; A61K0031-55
     [I,A]; A61K0031-553 [I,A]; A61K0045-06 [I,A]; A61P0025-24 [I,A]
CC   63-6 (Pharmaceuticals)
     Section cross-reference(s): 1
IT   5-HT antagonists
        (5-HT2; medicinal compns. containing adenosine A2A receptor
antagonists and
        other antidepressants)
IT   5-HT reuptake inhibitors
        (medicinal compns. containing adenosine A2A receptor antagonists and
other
        antidepressants)
IT   56296-78-7, Fluoxetine hydrochloride   99300-78-4, Venlafaxine
     hydrochloride   155270-99-8
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (medicinal compns. containing adenosine A2A receptor antagonists and
other
        antidepressants)


L11           8 S L1 AND (?SEROTONIN? OR ?TRYPTAMINE? OR 5-HT?)
L12           3 S L11 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
L13           0 S L12 NOT (L3 OR L8)

     FILE 'REGISTRY' ENTERED AT 11:31:44 ON 07 JUL 2011
                  E FLUOXETINE/CN

L14  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
RN   54910-89-3  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]-  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]-,
     (±)-
OTHER NAMES:
CN   (±)-Fluoxetine
CN   (±)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine
CN   3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
CN   Deprex
CN   dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
CN   Fluoxetin Ratiopharm
CN   Fluoxetine
CN   Fluoxin
CN   Fluval
CN   N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
CN   N-Methyl-3-[4-(trifluoromethyl)phenoxy]-3-phenylpropanamine
CN   Nikomed
CN   NSC 283480
CN   Seronil
CN   Symbiax
DR   57226-07-0, 52341-67-0
MF   C17 H18 F3 N O
```

CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSNB,
DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH,
IPA, MEDLINE, MRCK*, MSDS-OHS, PS, REAXYSFILE*, RTECS*, SPECINFO,
TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



L14 1 S E63
L15 0 S L1 AND L14
L16 1 S L1

FILE 'CAPLUS' ENTERED AT 11:32:20 ON 07 JUL 2011
L17 6 S L1 AND L14
L18 3 S L17 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
L19 1 S L18 NOT (L8 OR L3)
L20 1 S L19 NOT L10

L20 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN
AB Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist (e.g. a xanthine derivative) to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.

ACCESSION NUMBER: 2004:1080800 CAPLUS Full-text
DOCUMENT NUMBER: 142:33005
TITLE: A method using an adenosine A2A receptor antagonist for treating an anxiety disorder
INVENTOR(S): Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo; Kobayashi, Minoru; Kase, Junya
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108137	A1	20041216	WO 2004-JP8486	20040610

<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
AU 2004244906 A1 20041216 AU 2004-244906 20040610
<--
CA 2528710 A1 20041216 CA 2004-2528710 20040610
<--
EP 1631294 A1 20060308 EP 2004-746014 20040610
<--
EP 1631294 B1 20100915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
HR
CN 1787821 A 20060614 CN 2004-80012845 20040610
<--
BR 2004011120 A 20060718 BR 2004-11120 20040610
<--
JP 2006527264 T 20061130 JP 2006-516839 20040610
<--
AT 481101 T 20101015 AT 2004-746014 20040610
<--
ES 2349535 T3 20110104 ES 2004-746014 20040610
<--
US 20060281770 A1 20061214 US 2005-553250 20051017
<--
KR 2006037252 A 20060503 KR 2005-7021878 20051116
<--
MX 2005013148 A 20060317 MX 2005-13148 20051205
<--
ZA 2005009903 A 20100526 ZA 2005-9903 20051206
<--
NO 2005005907 A 20051213 NO 2005-5907 20051213
<--
IN 2006CN00077 A 20070629 IN 2006-CN77 20060106
<--
PRIORITY APPLN. INFO.: US 2003-509046P P 20030610
<--
US 2003-532793P P 20031224
<--
WO 2004-JP8486 W 20040610
<--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:33005
IPCI A61K0031-522 [ICM,7]; A61K0031-519 [ICS,7]; A61P0025-22 [ICS,7]
IPCR A61K0031-00 [I,A]; A61K0031-519 [I,A]; A61K0031-522 [I,A]; A61K0045-06
[I,A]; A61P0025-22 [I,A]
CC 1-11 (Pharmacology)
IT 69-89-6D, Xanthine, derivs. 51389-37-8 99331-25-6D,

Triazolopyrimidine, derivs. 155270-99-8 262452-04-0
377727-87-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A2A receptor antagonist for treating anxiety disorders)
IT 28981-97-7, Alprazolam 36505-84-7, Buspirone 54910-89-3,
Fluoxetine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A2A receptor antagonist for treating anxiety disorders,
and

```
                E KASE HIROSHI?/AU
L21           0 S E73-74,76
L22         241 S E73-E74,E76
                E KOBAYASHI MINORU?/AU
L23         438 S E85-E88
                E SHIOZAKI SHIZUO?/AU
L24          49 S E97-E98
                E MORI AKIHISA?/AU
L25         237 S E109-E112
                E SENO NAOKI?/AU
L26          53 S E121-E124
L27         977 S L22 OR L23 OR L24 OR L25 OR L26
L28           2 S L27 AND (L6 OR L7)
L29          11 S L27 AND (?SEROTONIN? OR ?TRYPTAMINE? OR 5-HT?)
L30          11 S L28 OR L29
L31          10 S L30 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
L32           9 S L31 NOT (L3 OR L8 OR L10)

     FILE 'CAPLUS' ENTERED AT 11:40:49 ON 07 JUL 2011
                E ADENOSINE RECEPTORS/IT
L33       64357 S E134,E139,E141
L34        8374 S ADENOSINE RECEPTORS/IT
L35       64357 S L33 OR L34
L36          68 S L27 AND L35
L37          63 S L36 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
L38          62 S L37 NOT (L3 OR L8 OR L10 OR L32)
L39           0 S L38 AND (?SEROTONIN? OR 5-HT? OR ?TRYPTAMIN?)
```